<DOC>
	<DOC>NCT01601613</DOC>
	<brief_summary>This trial is conducted in Asia. The aim of this is to investigate the efficacy and safety of activated recombinant human factor VII (rFVIIa) in achieving haemostasis in patients with Dengue haemorrhagic fever (DHF).</brief_summary>
	<brief_title>Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever</brief_title>
	<detailed_description />
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Hemorrhagic Fevers, Viral</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>Patients with the clinical diagnosis of Dengue Haemorrhagic Fever (DHF) Patients with a clinical diagnosis of DHF Grades II and III8, requiring standard replacement therapy Patients with a clinical diagnosis of DHF Grade IV Known or suspected allergy to trial product or related products Known hypersensitivity to mouse, hamster or bovine protein Prior treatment with activated recombinant human factor VII</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>